<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED):
MARCH 1, 2000 (FEBRUARY 23, 2000)
SPECTRX, INC.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
DELAWARE 0-22179 58-2029543
(STATE OR OTHER JURISDICTION OF (COMMISSION FILE ( I.R.S. EMPLOYER
INCORPORATION) NUMBER) IDENTIFICATION NO.)
6025 A UNITY DRIVE, NORCROSS, GA 30071
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES) (ZIP CODE)
REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE: 770-242-8723
- -------------------------------------------------------------------------------
(FORMER NAME OR FORMER ADDRESS, IF CHANGED SINCE LAST REPORT)
<PAGE> 2
Item 5. Other Events
On February 23, 2000 SpectRx, Inc. announced that it had completed a
private placement of 400,000 shares of the company's common stock, resulting in
gross proceeds to the company of $5 million, as more fully described in the
press release attached hereto as Exhibit 99.1, which is incorporated by
reference herein.
Item 7. Financial Statements and Exhibits.
(a) Financial statements of businesses acquired.
Inapplicable.
(b) Pro Forma financial information. Inapplicable.
(c) Exhibits.
The following exhibit is filed herewith:
Exhibit No. Exhibit Description
99.1 Press Release dated
February 23, 2000
<PAGE> 3
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
SpectRx, Inc.
Date: March 1, 2000 by: /s/ Thomas H. Muller, Jr.
-----------------------------------------
Thomas H. Muller, Jr.
Executive Vice President & Chief Fiancial Officer
and Secretary
<PAGE> 4
EXHIBIT INDEX
<TABLE>
<CAPTION>
EXHIBIT NO. EXHIBIT DESCRIPTION
- ----------- -------------------
<S> <C>
99.1 Press Release dated February 23, 2000
</TABLE>
<PAGE> 1
EXHIBIT 99.1
For Immediate Release Contacts: Bill Wells - Media
February 23, 2000 Thomas H. Muller, Jr. - Financial
(770) 242-8723
SPECTRX, INC. ANNOUNCES $5 MILLION PRIVATE PLACEMENT
NORCROSS, GA -- SpectRx, Inc. (NASDAQ: SPRX) today announced the
completion of a private placement of 400,000 shares of the company's common
stock. The stock was sold for $12.50 per share resulting in gross proceeds to
the company of $5 million. The funding was provided by a small group of private
investors. The purchasers were given registration rights under the company's
existing registration rights agreement. The funds will be used to support the
development of a non-invasive cervical cancer detection device and other
general corporate purposes.
SpectRx, Inc. is a leading biophotonics company that is focused on the
development and manufacture of painless and bloodless alternatives to medical
diagnostic and monitoring procedures. Biophotonics is the technology of using
light and other forms of energy to diagnose and monitor disease. SpectRx is the
developer of the BiliChekTM the world's first commercially available painless,
bloodless, non-invasive infant jaundice monitor. SpectRx is developing a
continuous glucose monitor with Abbott Laboratories (NYSE: ABT), a non-invasive
device that rapidly detects a previously unmeasured sign of diabetes with Roche
Diagnostics, and non-invasive cervical and skin cancer detection products with
Welch Allyn. For more information, visit the SpectRx web site at
www.spectrx.com.
Certain matters discussed in this announcement contain forward-looking
statements that involve material risks to, and uncertainties in the company's
business which may cause actual results to differ materially from those
anticipated by the statements made herein. The matters discussed herein should
be viewed together with the Risk Factors in the Company's 10K for the year
ending December 31, 1998 on file with the SEC.
